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Introduction: Up to 75% of the patients undergoing laparoscopic cholecystectomy develop postoperative
nausea and vomiting (PONV). Both ramosetron, a serotonin subtype 3 (5-HT3) antagonist, and dex-
amethasone are effective for PONV prophylaxis following laparoscopic cholecystectomy but their com-
bined effect has not been investigated. We investigated the efﬁcacy and tolerance of ramosetron alone
and ramosetron with dexamethasone for PONV prophylaxis after laparoscopic cholecystectomy.
Methods: Seventy six patients scheduled for laparoscopic cholecystectomy were randomized to receive
either intravenous (i.v.) 0.3 mg ramosetron (group R), or 8 mg dexamethasone plus 0.3 mg ramosetron
(group D). Standardized anesthesia with desﬂurane and remifentanil was used in all patients. Post-
operative nausea, retching, vomiting, rescue antiemetics, pain scores, rescue analgesics and side effects
were assessed at 0e2, 2e24 and 24e48 h postoperatively.
Results: Seventy two patients were randomized. The overall incidence of PONV did not differ (p ¼ 0.31)
but fewer patients needed rescue antiemetics in group D than in groups R (3 vs. 13 patients, respec-
tively; p ¼ 0.01) during 0e48 h postoperatively. Additionally, pain scores were signiﬁcantly lower in
group D during the study period (p < 0.01) and rescue analgesics were required less often in group D
during 2e48 h postoperatively (p < 0.01).
Conclusions: In patients undergoing laparoscopic cholecystectomy, the combined use of ramosetron and
dexamethasone was more effective than ramosetron alone for reducing the need for rescue antiemetics
and pain control following the procedure.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Laparoscopic cholecystectomy (LC) is frequently performed for
gallbladder stones or polyps. Postoperative nausea and vomiting
(PONV) is one of the most common adverse events after laparo-
scopic surgery with reported incidences of 40e75%.1 This unde-
sirable side effect may delay postoperative recovery and discharge,
so the prophylactic use of antiemetics for high-risk patients is
required to reduce hospital costs and increase patient satisfaction.2
In numerous investigations, PONV in patients scheduled for LC
has been prevented and treated with a variety of antiemetics
including anticholinergics,3 antihistamines,4 butyrophenones,5
benzamide,1,6 dexamethasone,7-9 and 5-HT3 antagonists.1,3,4,6,7
Among the numerous antiemetic therapies, a combination of: þ82 31 787 4063.
ciates Ltd. Published by Elsevier Lta serotonin receptor antagonist (e.g. ondansetron, granisetron,
tropisetron, dolasetron, and ramosetron) with dexamethasone is
considered to be highly effective for preventing PONV after LC.
Ramosetron, a 5-HT3 receptor antagonist, has prophylactic antie-
metic effects after LC.10 Dexamethasone, alone or in combination
with other 5-HT3 antagonists, is effective for preventing PONV, pain
control and improving the recovery proﬁle after LC.7e9
A Pubmed search using terms of “ramosetron” and “ dex-
amethason” revealed no studies of the combined effects of ramo-
setron plus dexamethasone for preventing PONV. We hypothesized
that a combination of dexamethasone and ramosetron would be
more effective for PONV prophylaxis and pain control than ramo-
setron alone after LC. Therefore, we designed and conducted
a prospective, randomized, and double-blind study to compare the
efﬁcacy and tolerability of intravenous (i.v.) ramosetron plus dex-
amethasone and ramosetron alone for the prophylaxis of PONV in
patients undergoing LC.d. All rights reserved.
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This prospective, randomized, and double-blind investigation was registered
with the Clinical Research information Service (CRiS, registration number
KCT0000267) and the study protocolwas approved by the Institutional Review Board
of Seoul National University Bundang Hospital (No. B-1109-135-301). After then,
informed consent from each patient, a total of 76 American Society of Anesthesiol-
ogist (ASA) physical status IeII subjects, aged 25e65 years, and scheduled for elective
LC under general anesthesia from October 2011 to January 2012 were enrolled.
Exclusion criteria included: gastrointestinal disease, obesity (more than 50% greater
than their ideal body weight), pregnancy or menstruation, history of motion sickness
and/or postoperative emesis, diabetes mellitus, use of steroids or antiemetics within
1 month of surgery and history of allergy to any study medication.
Patients were randomized to receive either intravenous ramosetron alone
(group R, n ¼ 38) or intravenous ramosetron plus dexamethasone (group D, n ¼ 38)
using a computer-generated randomization code (Random Allocation Software
Version 1.0) with block size 4. Randomizationwas performed before the induction of
anesthesia by an independent anesthesiologist who is responsible for patient allo-
cation and not otherwise involved in this study. Studymedications were prepared by
an anesthetic nurse not involved in this study. Study medications consisted of (1) an
identical syringe with 2 ml solution with normal saline for group R or 8 mg dex-
amethasone (Dexamethasone; Daewon Pharm., Seoul, Korea) for group D,
administered immediately after the induction of anesthesia and (2) a syringe with
2 ml solution with 0.3 mg ramosetron (Nasea injectable; Astellas Pharma Inc.,
Tokyo, Japan) which was injected at the end of surgery. Syringes were labeled with
the patient’s inclusion number and passed to the anesthesiologist. Patients, anes-
thesiologists, and outcome assessors were blinded to group assignment.
Patient received IV 0.03 mg/kg midazolam as a pre-anaesthestic medication. On
arrival in the operating room, standard monitors with continuous electrocardio-
gram, noninvasive blood pressure, pulse oximetry and capnography were applied to
the patient. Anesthesia was induced with i.v. 2 mg kg1 propofol and 3e4 ng ml1
remifentanil target-controlled infusion; 0.6 mg kg1 rocuronium was administered
prior to endotracheal intubation. Immediately after the induction of anesthesia,
study medication (normal saline or dexamethasone) was administered to the pa-
tient by the blinded anesthesiologist. Maintenance of anesthesia consisted of des-
ﬂurane 4.0e6.0% (inspired concentration), medical air in oxygen (FiO2 ¼ 0.5) and
IV remifentanil 2e3 ng ml1. Ventilation was mechanically controlled and an
end-tidal concentration of carbon dioxide was maintained between 4.5 and 5.0 kPa
throughout the surgery. Muscle relaxation was achieved with rocuronium, as
required. Nasopharyngeal temperature was monitored and maintained at 36e37 C
throughout the surgery using a warming pad. Lactated Ringer’s solutionwas infused
at the rate of approximately 10 ml kg1 h1 during the surgery. At the end of the
procedure, desﬂurane and remifentanil administration were discontinued and
0.3 mg ramosetronwas administered intravenously. Muscle relaxationwas reversed
with i.v. 0.01 mg kg1 glycopyrrolate and 0.04 mg kg1 neostigmine. Extubationwas
done after spontaneous ventilation of the patient became adequate.
Patients’ characteristics including age, gender, weight, height, non smoking
status, Apfel simpliﬁed risk scores11 and information on surgery and anesthesiawere
collected. All patients were transferred to the post-anesthesia recovery unit (PACU)
until they fulﬁll discharge criteria and then moved to the ward. Episodes of nausea,
retching and vomiting and the requirement of rescue antiemetics were recorded at
three assessment periods, 0e2 h, 2e24 h, and 24e48 h, by a nursing staff blinded to
treatment assignment. Nausea was deﬁned as a subjectively unpleasant inclination
to vomit; retchingwas deﬁned as an involuntary effort to vomit without expulsion of
gastric contents; vomiting was deﬁned as actual expulsion of gastric contents from
the mouth.12 The degree of nausea (NRS; numerical rating scale, with 0 ¼ none to
100 ¼ most severe) was assessed verbally in order to guide the need of rescue an-
tiemetics and this data was not part of analysis. The rescue antiemetic was i.v.
metoclopramide (10 mg), which was administered to patients with an NRS for
nausea > 30 or more than one episode of vomiting.
During the 0e48 h postoperative study period, patients were asked to evaluate
their level of postoperative pain verbally, using NRS (0¼ none to 100¼most severe).
An i.v. bolus dose of 30 mg ketorolac was administered to the patient with an NRS
>30. In addition, possible adverse effects related with ramosetron and dex-
amethasone, such as QTc interval prolongation, headache, dizziness, wound infec-
tion, stomach pain and increased appetite were also recorded.
In a preliminary study, 10 patients (with the same inclusion and exclusion cri-
teria) undergoing LC were administered IV ramosetron at the end of surgery and the
PONV incidence at postoperative 0e48 h was 40%. Reduction the incidence of PONV
from40% to 10%was considered to be clinically important. The analysis using sample
size software (PASS 2005, NCSS, USA) showed that 36 patients per group (power of
80% and type I error of 5%) would be sufﬁcient to detect the antiemetic effect of
ramosetron plus dexamethasone. Assuming a 5% dropout rate, the ﬁnal sample size
was set at 38 patients per group.
Analysis was performed using SPSS version 15.0 for Windows (SPSS, Chicago, IL,
USA). Student’s t-test (two-sided) was used to compare continuous variables (age,
weight, height, anesthesia time, operation time, dose rate of remifentanil, and pain
NRS). The Chi-square test was used to analyze categorical variables (gender, ASA class,
nonsmoking status, Apfel score, nausea, retching, vomiting, rescue antiemetics,rescue analgesics and adverse effects). Data are presented as mean (SD) or as count
(n). Two-sided P-values of <0.05 were considered statistically signiﬁcant.
3. Results
Of the 76 patients enrolled in this study, 4 patients were
excluded for conversion to open cholecystectomy (2 patients in
group R, 1 patient in group D) and protocol violations (1 patient in
group D, ondansetron as rescue antiemetic instead of metoclopra-
mide). A total of 72 patients were randomized to 1 of 2 study groups
(Fig. 1). Patient characteristics including age, weight, height, gen-
der, non smoking status, ASA class, Apfel scores and information on
surgery and anesthesia are presented in Table 1.
Cumulative results for the 0e48 h study period showed that
there was no difference in the overall incidence of PONV (p ¼ 0.31)
but the requirements for rescue antiemetics were lower in group D
than in groups R (13 patients for group R vs. 3 patients for group D;
p ¼ 0.01, Table 2).
The incidence of nausea of group D was comparable with that of
group R during the ﬁrst 24 h. However, the degree of nausea was
less severe and therefore rescue antiemetics were less required in
group D than in group R (8% [n ¼ 3] in group D vs. 33% [n ¼ 12] in
group R during the ﬁrst 2 h postoperatively [p ¼ 0.02], and 3%
[n ¼ 1] group D vs. 22% [n ¼ 8] in group R during the postoperative
2e24 h [p ¼ 0.03]). No inter-group difference was observed during
24e48 h postoperatively in the incidence of nausea and the need
for rescue antiemetics (p ¼ 1.0) (Table 2). Retching, vomiting, and
overall incidence of PONV were not different between the two
groups during 0e2, 2e24 and 24e48 h postoperatively (Table 2).
Pain scores during 0e2, 2e24 and 24e48 h were signiﬁcantly
lower in group D than in group R (p < 0.01, Table 3) and rescue
analgesics were required less frequently in group D than group
R during 2e24 (p < 0.01) and 24e48 h (p < 0.01, Table 3)
postoperatively.
No difference was observed in common adverse events related
to ramosetron or dexamethasone treatment between the two
groups. Headache (2 patients in group R and 1 patient in group D)
and dizziness (3 patients in group R and 1 patient in group D) were
the most common adverse effects (Table 3).
4. Discussion
The ﬁndings of this prospective, randomized, double-blind trial
revealed that a combination of ramosetron and dexamethasone
reduced the requirement for rescue aniemetics and postoperative
pain comparedwith ramosetron alone and caused no adverse effects
during the ﬁrst 48 postoperative hours in patients undergoing LC.
No control group was included in this study because patients
undergoing LC are at high risk of PONV with reported incidences
ranging from 75 to 83%8 and withholding prophylactic antiemetics
from these patients would be unethical. Besides the general risk
factors of PONV such as female gender, a history of motion sickness
or PONV, nonsmoking status and the use of postoperative opioid,11
prolonged carbon dioxide insufﬂations and increased intracranial
pressure by cerebral vasodilation may contribute to the high inci-
dence of PONV after LC.13 The 5-HT3 antagonists ramosetron has
been administered as an antiemetic after LC10 and combined
antiemetic agents targeting different receptors are recommended
for prophylactic use in groups at high risk of PONV.2 The gluco-
corticoid, dexamethasone produces an antiemetic effect, possibly
via the release of endorphin and inhibition of prostaglandin and
serotonin production.14 In this study, the incidence of PONV for 48 h
postoperatively was 39% with ramosetron alone and 28% with
ramosetron plus dexamethasone. The addition of dexamethasone
to ramosetron did not reduce the overall incidence of PONV
Fig. 1. Flow diagram of patients. Seventy six patients were randomized. Three patients (2 patients from R group and 1 patient from D group) were eliminated due to conversion to
open cholecytectomy and 1 patient was excluded from the analysis due to protocol violation (ondansetron administration instead of metoclopramide as a rescue antiemetic). R
group; ramosetron alone group. D group: dexamethasone plus ramosetron group.
Table 2
Incidences of PONV and rescue analgesic. Group R; i.v. ramosetron 0.3 mg alone
group. Group D; i.v. dexamethasone 8 mg combined with ramosetron 0.3 mg group.
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and consequently reduced the need for recue analgesics compared
with ramosetron alone 0e24 h postoperatively. This result is not in
line with the results of previous studies, in which dexamethasoneTable 1
Patients’ characteristics and information on surgery and anaesthesia. Group R; i.v.
ramosetron 0.3 mg alone group. Group D; IV dexamethasone 8 mg combined with
ramosetron 0.3 mg group. ASA; American Society of Anesthesiologists. Values are
expressed as mean (SD) or number of the patients (%). Data were analyzed using t-
test (continuous variables) or Chi-square test (incidence variables).
Group R (n ¼ 36) Group D (n ¼ 36)
Age (yr) 44 (20e65) 45 (24e64)
Weight (kg) 70 (12) 66 (11)
Height (cm) 165 (10) 164 (8)
Male/Female (%) 16/20 19/17
Non smoking status, n, (%) 30 (83) 29 (81)
Apfel Score, n, (%)
0 6 (17) 7 (19)
1 10 (28) 12 (33)
2 20 (56) 17 (47)
Preoperative diagnosis, n, (%)
Gallbladder stone 18 (50) 20 (56)
Gallbladder polyp 6 (17) 10 (28)
Acute cholecystitis 9 (25) 4 (11)
Chronic cholecystitis 3 (8) 2 (6)
Operation time (min) 48 (22) 48 (18)
Anaesthesia time (min) 80 (24) 82 (21)
Remifentanil (mg kg1min1) 0.14 (0.1) 0.11(0.02)
ASA physical status I/II, n, (%) 23 (64)/13 (36) 22 (61)/14 (39)
N/A; not applicable. Values are expressed as number of the patients (%). Data were
analyzed using Chi-square test.
Group R (n ¼ 36) Group D (n ¼ 36) P value
Postoperative 0e48 h
Nausea 14 (39) 9 (25) 0.31
Retching 2 (6) 1 (3) >0.99
Vomiting 2 (6) 0 (0) 0.25
Rescue antiemetic 13 (36) 3 (8) 0.01
PONV 14 (39) 9 (25) 0.31
Postoperative 0e2 h
Nausea 13 (36) 9(25) 0.44
Retching 1 (3) 0 (0) >0.99
Vomiting 0 (0) 0 (0) N/A
Rescue antiemetic 12 (33) 3 (8) 0.02
PONV 13 (36) 9 (25) 0.44
Postoperative 2e24 h
Nausea 10 (28) 3 (8) 0.06
Retching 1 (3) 1 (3) 1 > 0.99
Vomiting 2 (6) 0 (0) 0.49
Rescue antiemetic 8 (22) 1 (3) 0.03
PONV 10 (28) 3 (8) 0.06
Postoperative 24e48 h
Nausea 1 (3) 1 (3) >0.99
Retching 0 (0) 0 (0) N/A
Vomiting 0 (0) 0 (0) N/A
Rescue antiemetic 1 (3) 0 (0) >0.99
PONV 1 (3) 1 (3) >0.99
Table 3
Postoperative pain scores and adverse effects. Group R; i.v. ramosetron 0.3 mg alone
group. Group D; i.v. dexamethasone 8 mg combined ramosetron 0.3 mg group.
Values are expressed as mean (SD) or number of the patients (%). NRS; numerical
rating scale. N/A; not applicable. Data were analyzed using t-test (pain NRS) or Chi-
square test (incidence variables).
Group R (n ¼ 36) Group D (n ¼ 36) P value
Postoperative 0e2 h
Pain (NRS) 82 (13) 68 (14) <0.01
Rescue analgesic 36 (100) 36 (100) N/A
Headache 2 (6) 1 (3) >0.99
Dizziness 3 (8) 1 (3) 0.61
Postoperative 2e24 h
Pain (NRS) 44 (13) 30 (12) <0.01
Rescue analgesic 32 (89) 19(53) <0.01
Headache 2 (6) 1 (3) >0.99
Dizziness 0 (0) 0 (0) N/A
Postoperative 24e48 h
Pain (NRS) 21 (16) 10 (8) <0.01
Rescue analgesic 14 (39) 0 (0) <0.01
Headache 0 (0) 0 (0) N/A
Dizziness 0 (0) 0 (0) N/A
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PONV in patients undergoing thyroidectomy15 or laparoscopic
surgery.8,16
The ramosetron plus dexamethasone group had lower pain
scores during the study period (0e48 h postoperatively) and
required less rescue analgesics for 2e48 h postoperatively than the
ramosetron alone group. Although the groups did not differ in the
need of rescue analgesic during early postoperative period (0e2 h),
the ramosetron plus dexamethasone group scored signiﬁcantly
lower for pain than the ramosetron alone group during this period.
Several randomized controlled studies and meta-analyses have
found that single-dose dexamethasone is effective in postoperative
pain control after various surgeries including laparoscopic, breast
and thyroid surgeries.9,15,17e20 Possible mechanisms for this are its
anti-inﬂammatory action and modulation of the systemic physio-
logical responses.14 In this study, dexamethasone was administered
immediately after induction of anesthesia and was effective in
reducing the pain scores at 48 h postoperatively. After LC, patients
frequently complain of severe early postoperative pain due to car-
bon dioxide pneumoperitoneum and stretching of the abdominal
wall.21 However, opioid-based analgesia administered via bolus in-
jection or patientecontrolled analgesia may carry a greater risk of
PONV in these high-risk patients. Therefore, dexamethasone treat-
ment may be beneﬁcial for patients without patientecontrolled
analgesia after LC in that it provides pain relief and reduced the
need for analgesics.
We monitored the patients for major adverse effects related to
ramosetron and dexamethasone such as headache, dizziness,
wound infection, stomach pain and increased appetite and QTc
prolongation for 48 h postoperatively. Both drugs were well tol-
erated during the study period: three cases of headache and four
cases of dizziness and the addition of dexamethasone to ramose-
tron did not affect the incidence of adverse events. Although pro-
longed glucocorticoid use may cause infection, delayed wound
healing, glucose intolerance, and adrenal suppression, a single dose
of dexamethasone is rarely associated with theses these serious
side effects.14 Patients with diabetes mellitus were excluded from
this study because of concerns regarding hyperglycemia.
The timing of the administration and dose (8 mg) of dex-
amethasone were based on previous studies20,22 that reported
a perioperative antiemetic effect. A meta-analysis of perioprative
single-dose dexamethasone for postoperative pain also found that
intermediate-dose dexamethasone (0.11e0.2 mg/kg) had opioid-
sparing effects.18 Dexamethasone is most effective for PONV andanalgesia when administered at the time anesthesia induc-
tion7,8,15,19,20,22 considering its onset of action and the duration of
anesthesia.
This study had some limitations. First, preoperative dex-
amethasone administration was reported to enhance the recovery
from surgery7,23 and reduce PONV and postoperative pain. How-
ever, we did not assess the discharge time from PACU or hospital
stay, nor did we evaluate quality of recovery (such as patients’
satisfaction, shivering, fatigue, or sense of well-being). Second, we
only observed patients for 48 h postoperatively and long-term
complications of glucocorticoid including wound infection and
impaired wound healing may be underestimated in this period.
Third, patients with diabetes mellitus were excluded from this
study as previous studies reported that i.v. dexamethasone 8 mg
administered at the beginning of surgery resulted in signiﬁcantly
increased postoperative blood glucose concentrations.24,25
5. Conclusion
In conclusion, combined i.v. 0.3 mg ramosetron and 8 mg dex-
amethasone was more effective than 0.3 mg i.v. ramosetron alone
for the relief of nausea and pain during the ﬁrst 48 postoperative
hours in patients with LC without increasing adverse effects. No
clinically signiﬁcant adverse effects were observed in this study and
i.v. dexamethasone and ramosetron appear to be well tolerated in
these patients.
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